Apple’s decision to tighten oversight on medical device apps from spring 2026 marks a major shift in how digital health is governed. By requiring formal declarations and proof of regulatory approvals like CE or UKCA marks directly within the App Store, Apple is effectively moving from a simple distributor to an active gatekeeper. For developers in the UK, US, and Europe, this means clinical validity and safety documentation can no longer be a final checkbox, they must be central to the development process.
At International Associates, we are already helping companies navigate this new layer of scrutiny. As an Authorised Representative, we ensure your technical files and certifications are robust enough to satisfy both national regulators and platform requirements, keeping your path to market clear. If you are preparing for these changes and require professional guidance to manage your regulatory pathways, please get in touch with our team to discuss how we can support your transition.